Please assess the completion status of the following clinical trial:

Trial Title: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 to 65 years of age, inclusive~* Inactive CHB with documented HBsAg positivity for at least 12 months before Day 1~* qHBsAg ≥ 10 IU/mL but ≤ 100 IU/mL in the 12 months prior to screening~* HBV DNA ≥ 10 IU/mL at screening~* AST, ALT, INR, albumin, total bilirubin (excluding patients with Gilbert Syndrome) and direct bilirubin within normal limits at screening~Exclusion Criteria:~* Positive hepatitis B e antigen (HBeAg) at screening~* History of a hepatitis B flare or 1-log increase in HBV DNA or HBsAg in the prior 12 months~* Undetectable HBV DNA at screening~* Fibroscan \> 8.5 kPA at screening, or history of hepatic fibrosis or cirrhosis (NB, a Fibroscan is not required if an examination is performed within 12 months or a liver biopsy was performed within 2 years before Screening and no fibrosis \[F1 or greater\] was identified).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HepTcell (Type: EXPERIMENTAL): Dose administered at intervals of 4 weeks for 6 doses
- Placebo (Type: PLACEBO_COMPARATOR): Dose administered at intervals of 4 weeks for 6 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).